TCT-176 Implantation of Thin-Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With De Novo Coronary Artery Lesions: 2-Year Clinical and 6-Month Imaging Outcomes of the MeRes-1 Extend Trial

The development of bioresorbable vascular scaffold (BRS) offers a new treatment strategy for coronary artery lesion by replacement of a permanent metallic scaffold with a temporary scaffold and eradicating a nidus for very late adverse events. The first-in-human MeRes-1 trial reported favorable